 | Up a level |
2019
Thunnissen, E., Lissenberg-Witte, B., I, van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sorensen, J. B., Mellemgaard, A., Dingemans, A. M. C., Speel, E. J. M., de Langen, A. J., Hashemi, S. M. S., Bahce, I, van der Drift, M. A., Looijen-Salamon, M. G., Gosney, J., Postmus, P. E., Samii, S. M. S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Grady, A. O., Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I, Heukamp, L. C., Timens, W., Schuuring, E. M. D., Pauwels, P. and Smit, E. F. (2019). ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 138. S. 13 - 19. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332